MedPath

A Study in Healthy Men to Test Whether Bosentan Influences the Amount of BI 425809 in the Blood

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BI 425809
Drug: bosentan
Registration Number
NCT05723874
Lead Sponsor
Boehringer Ingelheim
Brief Summary

The main objective of this trial is to investigate the relative bioavailability of BI 425809 given alone (Reference) compared to a combined administration with the moderate CYP3A4 inducer bosentan (Test) following repeated oral administration.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
14
Inclusion Criteria
  • Healthy male subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead electrocardiogram (ECG), and clinical laboratory tests
  • Age of 30 to 55 years (inclusive)
  • Body mass index (BMI) of 18.5 to 29.9 kg/m2 (inclusive)
  • Signed and dated written informed consent in accordance with International Council for Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial
Read More
Exclusion Criteria
  • Any finding in the medical examination (including BP, PR or ECG) deviating from normal and assessed as clinically relevant by the investigator
  • Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 millimetre of mercury (mmHg), or pulse rate outside the range of 45 to 90 beats per minute (bpm)
  • Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
  • Any evidence of a concomitant disease assessed as clinically relevant by the investigator
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)
  • Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
  • History of relevant orthostatic hypotension, fainting spells, or blackouts
  • Further exclusion criteria apply
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Period 2 (Test treatment (T)): bosentan + BI 425809BI 425809-
Period 1 (Reference treatment (R)): BI 425809BI 425809-
Period 2 (Test treatment (T)): bosentan + BI 425809bosentan-
Primary Outcome Measures
NameTimeMethod
Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ (AUCτ,ss)On Day 10 of period 1 and on Day 14 of period 2.
Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ (Cmax,ss)On Day 10 of period 1 and on Day 14 of period 2.
Secondary Outcome Measures
NameTimeMethod
Minimum concentration of the analyte in plasma at steady state within a uniform dosing interval τ (Cmin,ss)On Day 10 of period 1 and on Day 14 of period 2.

Trial Locations

Locations (1)

Humanpharmakologisches Zentrum Biberach

🇩🇪

Biberach, Germany

© Copyright 2025. All Rights Reserved by MedPath